Sonnet biotherapeutics announces pharmacokinetic and pharmacodynamic data in a phase 1 dose-escalation trial of son-1010

24 healthy volunteers have been dosed in study sb102 to assess the safety, pk, and pd of son-1010 without the background of prior chemotherapy pk data shows an extended half-life of son-1010 of approximately 112 hours, compared to 12 hours for rhil-12 simulation of the controlled and prolonged induction of ifng and minimal related adverse events suggest that dose escalation can continue princeton, nj / accesswire / january 19, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company" or "sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (pk) profile simulation of son-1010 dosing has been completed in its randomized, placebo-controlled phase 1 clinical trial in healthy volunteers. historically, the therapeutic application of cytokines has been limited by relatively short half-lives and off-target toxicities that are typically associated with peak plasma levels.
SONN Ratings Summary
SONN Quant Ranking